Abstract

Glioma, especially glioblastoma, is pathologically characterized by high aggressiveness, which largely contributed to the ineffectiveness of current therapies. It has been recently reported that intrinsic PD-L1 can regulate tumor malignancy, whereas underlying mechanisms remain mostly unclear. Here, we report a novel mechanism by which PD-L1 promotes glioma cell infiltration. In orthotopic glioma models, PD-L1 expression was up-regulated predominantly in glioma cells in the infiltrating front. For PD-L1-overexpressed glioma cells, PI3K/Akt and actin regulations were among the top six most altered signaling pathways as detected by RNA-sequencing. PD-L1 significantly activated Akt/F-actin signaling while suppressed autophagic signaling upon cell starvation. Mechanistically, PD-L1 preferentially bound to Akt among various PI3K/Akt signaling proteins. Serial truncation identified the interaction between the 128-237aa fragment of PD-L1 and the 112-480aa fragment of Akt, which facilitates the membrane translocation/activation of Akt, and was unaffected by Perifosin (specific p-Akt inhibitor targeting Akt PH-domain). Taken together, our data indicate that in glioma cells, PD-L1 is induced to prevent autophagic cytoskeleton collapse via Akt binding/activation, facilitating glioma cell invasion upon starvation stress.

Highlights

  • Glioma, the most common primary intracranial tumor, originates from various types of cells

  • To ascertain the relationships between intrinsic PD-L1 and glioma cell invasive behavior during glioblastoma multiforme (GBM) development, we examined PD-L1 expression in the whole brain at various stages of GBM development in a highly aggressive orthotopic

  • Since PI3K/Akt signaling is pivotal in promoting cell survival and suppressing autophagy [6, 33], we further investigated the role of PD-L1 in regulating Akt-autophagic influx signaling in glioma cells with a EBSSinduced starvation model

Read more

Summary

Introduction

The most common primary intracranial tumor, originates from various types of cells. The most malignant glioma is glioblastoma, or glioblastoma multiforme (GBM), which accounts for around 21% of glioma and can be primary or secondary from grade II-III glioma. Glioma is classified into three types based on its molecular markers: 1p/19q deletion, IDH mutation and TERT promoter mutation. Grade IV glioma mainly has the TERT promoter mutation accompanied by EGFR/PTEN mutation. Current treatments for glioma remain conventional surgery, radiotherapy and chemotherapy. Glioma is extremely easy to relapse after treatment, with an average survival time of only 14 months for GBM patients after treatment [1]. It is urgent to find new and effective therapies in order to prolong the survival time of GBM patients

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call